New Perspectives in the Treatment of Thoracic Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 1 September 2025 | Viewed by 694
Special Issue Editors
Interests: lung cancer; thymic malignancies; pulmonary metastases; thoracic ultrasonography
Interests: lung cancer; thoracic surgery; thymic malignancies; minimally invasive thoracic surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Thoracic cancers encompass a wide category of malignancies that arise from several different organs. While primary or secondary lung tumors represent the vast majority of intrathoracic cancers, with an impressively high burden of morbidity and mortality, tumors arising from the thymus or pleura are less common but offer engaging insights on the relationship between cancer and host. Historically, tumors in early stages are usually treated with surgery upfront, while multimodality approaches represent the key in the management of more advanced cancer conditions. However, recent technological advancements, the introduction of novel, highly effective anticancer molecules, and the inceptive application of artificial intelligence (AI) protocols in medical sciences have enhanced our understanding and re-drawn our perspectives in the treatment of intrathoracic malignancies.
The scope of this Special Issue is therefore to discover the most recent achievements and findings in the treatment of thoracic malignancies and to explore their potential impact in redefining the current management guidelines of these conditions.
Dr. Francesco Londero
Dr. Francesco Guerrera
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- pulmonary metastases
- thymic malignancies
- malignant mesothelioma
- immunotherapy
- target therapy
- artificial intelligence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
